Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical TrialAndrew Ahmann, Vanita R. Aroda, Elena Henkel et al.|Diabetes Care|2017Cited by 574
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trialsVanita R. Aroda, Ildiko Lingvay, Andrew Ahmann et al.|Diabetes & Metabolism|2019Cited by 281